Drug Trial Radar · NCT06142175
Relmacabtagene Autoleucel in Patients With LBCL
Last checked: Nov 19, 2026Latest source record: Mar 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
200
Planned (sponsor's estimate)
Start
Dec 28, 2022
Primary completion
Dec 31, 2024
Study completion Dec 31, 2024
Sponsor
- Lead sponsor
- Shanghai Ming Ju Biotechnology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 21, 2023
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of Relmacabtagene autoleucel for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) in real-world
Conditions
- Large B-cell Lymphoma
Interventions
Relmacabtagene AutoleucelBiological
A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORRTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.